大分割累及野放疗联合同期化疗治疗局部晚期非小细胞肺癌的II期研究
这项单中心单臂II期研究纳入36例IIIA/IIIB期局部晚期非小细胞肺癌患者,采用2.5 Gy分次的大分割累及野放疗(中位总剂量67.5 Gy)联合同期化疗。1、3、5年总生存率分别为88.9%、61.1%、54.1%,中位无进展生存期10.7个月,3级放射性肺炎发生率8.3%,未观察到4级及以上急性或晚期毒性。
要点
- 2.5 Gy分次大分割累及野放疗联合同期化疗,3级放射性肺炎发生率为8.3%。
- 1、3、5年总生存率分别为88.9%、61.1%、54.1%,中位无进展生存期10.7个月。
- 未观察到4级或5级急性及晚期毒性,安全性可接受。
核心结论
- 大分割累及野放疗(HypoFx-IFRT)联合同期化疗安全性可接受,可能有利于局部晚期非小细胞肺癌(LA-NSCLC)患者的生存结局。
研究设计与样本
- 前瞻性、单中心、单臂II期试验,2010年启动,最终入组并评估36例IIIA和IIIB期LA-NSCLC患者。
- 全部患者接受三维适形放疗的大分割累及野放疗,中位总剂量67.5 Gy(范围60-70 Gy),分次剂量2.5 Gy,联合同期化疗。
- 因入组缓慢试验提前关闭;全组中位随访50个月,存活患者中位随访65个月。
主要发现
- 1年、3年、5年总生存率分别为88.9%(95%CI 78.6%-99.2%)、61.1%(95%CI 45.2%-77.0%)、54.1%(95%CI 37.3%-70.9%)。
- 中位总生存时间未达到,中位无进展生存时间为10.7个月。
- 3级放射性肺炎、食管炎和食管狭窄发生率分别为8.3%、2.8%和2.8%,未观察到4级或5级急性或晚期毒性。
关键数值与推荐
- HypoFx-IFRT采用2.5 Gy分次,中位总剂量67.5 Gy(范围60-70 Gy),目标为治疗交付时间不超过6周。
- 3级放射性肺炎发生率8.3%,3级食管炎2.8%,3级食管狭窄2.8%。
临床怎么用
- 对于局部晚期III期非小细胞肺癌,可考虑2.5 Gy分次的大分割累及野放疗联合同期化疗,但需注意该方案来自小样本单臂研究。
- 治疗中关注放射性肺炎和食管毒性,本研究中3级放射性肺炎发生率为8.3%。
局限性
- 单中心、单臂设计,样本量仅36例,且因入组缓慢提前关闭,证据级别有限。
- 随访时间在全组为50个月,存活患者为65个月,长期生存与晚期毒性数据仍需更长期观察。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This phase II study aimed to evaluate the efficacy and safety of hypofractionated involved-field radiation therapy (HypoFx-IFRT) in 2.5 Gy fractions and concurrent chemotherapy for locally advanced stage IIIA and B nonsmall cell lung cancer (LA-NSCLC) without prolonging treatment delivery time beyond 6 weeks. We analyzed the overall survival (OS), progression-free survival, and safety of the treatment. METHODS AND MATERIALS: This prospective, single center, single-arm trial was initiated in 2010. All LA-NSCLC patients were treated with HypoFx-IFRT using 3-dimensional conformal radiation therapy. The median total dose of HypoFx-IFRT was 67.5 Gy (range, 60-70). RESULTS: From December 2010 to October 2016, 36 patients were ultimately enrolled and evaluated. The trial closed early owing to slow accrual. The median follow-up duration was 50 months in all patients and 65 months in surviving patients. The 1-, 3-, and 5-year OS rates were 88.9% (95% confidence interval [CI], 78.6%-99.2%), 61.1% (95% CI, 45.2%-77.0%), and 54.1% (95% CI, 37.3%-70.9%), respectively. The median time for OS was not reached. The median time for progression-free survival was 10.7 months. The incidence rates of grade 3 radiation pneumonitis, esophagitis and esophageal stenosis were 8.3%, 2.8%, and 2.8%, respectively, and no acute or late toxicities of grade 4 or 5 were observed. CONCLUSIONS: This study indicated that HypoFx-IFRT with concurrent chemotherapy yielded an acceptable safety profile and might be beneficial in the survival outcomes of patients with LA-NSCLC.
引用
- Katsuta T, Matsuura K, Kashiwado K, et al. Phase II Study: The Outcome of Hypofractionated Involved-Field Radiation Therapy With Concurrent Chemotherapy for the Treatment of Locally Advanced Non-small Cell Lung Cancer. Pract Radiat Oncol. 2020. PMID: 32949771. doi:10.1016/j.prro.2020.09.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。